Pulmonary Fibrosis - 43 Studies Found
| RECRUITING |
: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis : Progressive Pulmonary Fibrosis : 2024-11-21 : Specified dose on specified days |
| RECRUITING |
: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity).300 mg EGCG (2 capsules) taken orally daily for 12 weeks.Dru |
| RECRUITING |
: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Orally via a tablet. |
| RECRUITING |
: A Study to Investigate Leramistat in Patients With IPF : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Drug: Leramistat |
| RECRUITING |
: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) : Progressive Pulmonary Fibrosis : 2024-11-21 : Placebo administered QID |
| RECRUITING |
: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Vixarelimab will be administered as per the schedule specified in the respective arms. |
| COMPLETED |
: Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis : Idiopathic Pulmonary Fibrosis : 2024-11-21 : A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer. |
| RECRUITING |
: Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Nitric oxide gas for inhalation |
| COMPLETED |
: SVF for Treating Pulmonary Fibrosis Post COVID-19 : Pulmonary Fibrosis : 2024-11-21 : Subjects received an intravenous injection of autologous adipose-derived SVF. |
| COMPLETED |
: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF : Idiopathic Pulmonary Fibrosis : 2024-11-21 : Intravenous administration of a starting dose of the monoclonal antibody |